Precision medicine is the matching of therapy (such as a drug) with specific aspects of a patient’s disease. Most of these ‘targeted therapies’ are designed to hit a single target, such as KRAS. While a promising approach, these drugs have overall proved limited in providing sustained benefit to the patient.

At the McNab, we aim to develop a next generation of drugs that address cancer in the context of the whole body. How? By combining artificial intelligence, sophisticated cancer models, and robotics-based chemistry (Prof. Cronin’s ‘Chemputer’), we seek to use our unique ‘Chemical Evolution’ approach to find new therapeutic spaces. This futuristic approach is unique to the McNab.